SecBot SecBot
SECBOTREPLAY Home › Report › HALO

HALO · Halozyme announced that Johnson & Johnson received FDA accelerated…

Halozyme Therapeutics, Inc. · PRESS-RELEASE filed Nov 6, 2026 at 09:57 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Nov 6, 2026 at 09:57 ET

Halozyme announced that Johnson & Johnson received FDA accelerated approval for RYBREVANT FASPRO (amivantamab co-formulated with Halozyme's ENHANZE technology) for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after prior chemo and anti-PD-(L)1 therapy. This is the first approval of a dual-targeted therapy in this setting and expands the commercial reach of Halozyme's ENHANZE platform beyond lung cancer.

  • FDA accelerated approval for RYBREVANT FASPRO (amivantamab + hyaluronidase-lpuj) in recurrent/metastatic HNSCC after platinum chemo and anti-PD-(L)1 failure
  • First dual-targeted therapy (EGFR/MET) approved in this setting
  • Co-formulated with Halozyme's ENHANZE drug delivery technology
  • Approval expands ENHANZE's commercial reach beyond lung cancer into a new indication with high unmet need

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access